8.2.2 Beta Agonists Summary

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/33

encourage image

There's no tags or description

Looks like no tags are added yet.

34 Terms

1
New cards

Primary therapeutic purpose of β2‑agonists in asthma/COPD?

Relieve bronchoconstriction by relaxing bronchial smooth muscle.

2
New cards

Location of β2 receptors targeted for asthma treatment?

Bronchial smooth muscle in the lung.

3
New cards

Sequence of intracellular events after β2 receptor activation?

G‑protein activation → adenylyl cyclase → increased cAMP → activation of protein kinase A → reduced intracellular calcium → smooth muscle relaxation.

4
New cards

Functional result of increased cAMP and PKA activation in airway smooth muscle?

Reduced myosin light chain kinase activity, leading to bronchodilation.

5
New cards

Additional mechanism of cAMP related to inflammation?

Inhibits release of mediators from mast cells.

6
New cards

Define SABAs and their clinical role.

Short‑acting β2‑agonists used for immediate symptom relief and rescue therapy.

7
New cards

Examples of SABAs.

- Albuterol

- salbutamol

- terbutaline

- epinephrine

- isoproterenol.

8
New cards

Typical duration of action for SABAs.

Less than two hours.

9
New cards

Reason SABAs used for emergencies.

Fast onset and quick relaxation of airway smooth muscle.

10
New cards

Define LABAs and their clinical role.

Long‑acting β2‑agonists used for maintenance and prevention of chronic symptoms.

11
New cards

Examples of LABAs.

- Salmeterol

- olodaterol

- formoterol

- vilanterol

- indacaterol

12
New cards

Reason LABAs are long‑acting.

Long pulmonary residence time.

13
New cards

Why formoterol is used with budesonide in mild asthma?

Faster onset of action allows symptom relief with continued maintenance.

14
New cards

Two major inhalation delivery devices for β2‑agonists.

Metered‑dose inhalers and dry powder inhalers.

15
New cards

Characteristic of dry powder inhalers.

Breath‑activated; effectiveness depends on inhalation flow rate.

16
New cards

Population where DPI may be less effective.

Patients with severe airflow limitation.

17
New cards

Purpose of a spacer with MDIs.

Improves lung deposition and reduces drug in mouth and throat.

18
New cards

Desired receptor selectivity profile for β2‑agonists.

High β2 affinity and low β1 affinity.

19
New cards

Reason high β1 affinity is undesirable.

Increases heart rate and cardiovascular side effects.

20
New cards

Typical clinical use of SABAs.

Rescue medication for acute bronchoconstriction.

21
New cards

Typical clinical use of LABAs.

Maintenance therapy for moderate to severe persistent asthma or COPD.

22
New cards

Most common adverse effect of β2‑agonists.

Tremor from β2 stimulation in skeletal muscle.

23
New cards

Cardiac side effect of β2‑agonists and reason.

Tachycardia due to stimulation of β1 and β2 receptors in the heart.

24
New cards

Metabolic side effects linked to β2‑agonists.

Hyperglycemia and reduced plasma potassium.

25
New cards

Other possible side effects.

Headache, bronchospasm, dizziness, pharyngitis, pain.

26
New cards

Original concern leading to FDA black box for LABAs.

Increased asthma‑related deaths when LABAs used alone.

27
New cards

Reason FDA removed black box for combination LABA + corticosteroid products.

Studies showed no increased risk when LABAs only used with corticosteroids.

28
New cards

Does black box warning still apply to LABA monotherapy?

Yes.

29
New cards

Metabolic pathway important for β2‑agonist interactions.

CYP3A4.

30
New cards

Potent CYP3A4 inhibitors that increase β2‑agonist systemic levels.

Ketoconazole and ritonavir.

31
New cards

Drugs requiring extreme caution because they potentiate vascular effects of salmeterol.

MAO inhibitors and tricyclic antidepressants.

32
New cards

Effect of combining β‑blockers with β2‑agonists.

Blocks bronchodilation and may cause severe bronchospasm.

33
New cards

Interaction with digoxin.

May decrease digoxin levels.

34
New cards

Interaction with diuretics.

May worsen hypokalemia.